CO6410281A2 - Suspensiones acuosas de riluzol - Google Patents

Suspensiones acuosas de riluzol

Info

Publication number
CO6410281A2
CO6410281A2 CO11107620A CO11107620A CO6410281A2 CO 6410281 A2 CO6410281 A2 CO 6410281A2 CO 11107620 A CO11107620 A CO 11107620A CO 11107620 A CO11107620 A CO 11107620A CO 6410281 A2 CO6410281 A2 CO 6410281A2
Authority
CO
Colombia
Prior art keywords
riluzol
suspensions
riluzole
waterproof
waterproof suspensions
Prior art date
Application number
CO11107620A
Other languages
English (en)
Inventor
Roberta Artico
Marco Adami
Paolo Mascagni
Oldoni Tiziano
Del Prado Jaime Moscoso
Daniele Barbareschi
Original Assignee
Italfarmaco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40810549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6410281(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Italfarmaco Spa filed Critical Italfarmaco Spa
Publication of CO6410281A2 publication Critical patent/CO6410281A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se divulgan suspensiones física y químicamente estables de Riluzol, junto con los métodos de fabricación de las mismas. Tales suspensiones acuosas contienen Riluzol en forma de partículas y por lo menos un agente humectante, preferiblemente un surfactante. El Riluzol está en cantidades desde alrededor de 0.1% a alrededor de 20% p/v y tiene un tamaño promedio de partícula menor que 200 µm; tales suspensiones están desprovistas de los efectos anestésicos locales (en la boca) del Riluzol.
CO11107620A 2009-03-13 2011-08-24 Suspensiones acuosas de riluzol CO6410281A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09425101A EP2228054A1 (en) 2009-03-13 2009-03-13 Riluzole aqueous suspensions

Publications (1)

Publication Number Publication Date
CO6410281A2 true CO6410281A2 (es) 2012-03-30

Family

ID=40810549

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11107620A CO6410281A2 (es) 2009-03-13 2011-08-24 Suspensiones acuosas de riluzol

Country Status (22)

Country Link
US (1) US8765150B2 (es)
EP (2) EP2228054A1 (es)
JP (1) JP5607083B2 (es)
KR (1) KR101680175B1 (es)
CN (1) CN102341091B (es)
BR (1) BRPI1006418A2 (es)
CA (1) CA2748856C (es)
CL (1) CL2011002217A1 (es)
CO (1) CO6410281A2 (es)
CY (1) CY1113825T1 (es)
DK (1) DK2405890T3 (es)
ES (1) ES2400349T3 (es)
HK (1) HK1161985A1 (es)
HR (1) HRP20130021T1 (es)
MX (1) MX2011008922A (es)
PE (1) PE20120649A1 (es)
PL (1) PL2405890T3 (es)
PT (1) PT2405890E (es)
RU (1) RU2498802C2 (es)
SI (1) SI2405890T1 (es)
SM (1) SMT201300022B (es)
WO (1) WO2010102923A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014000742A2 (pt) * 2011-07-13 2016-08-23 Andrew A Wolff terapia de combinação de als
US10357497B2 (en) * 2012-06-23 2019-07-23 Biohaven Pharmaceutical Holding Company Limited Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
EP3023093B1 (en) * 2014-11-20 2017-07-26 S.I.I.T. S.r.l.-Servizio Internazionale Imballaggi Termosaldanti Medicinal preparation based on diosmectite
SI3220891T1 (sl) 2014-11-21 2020-02-28 Biohaven Therapeutics Ltd. Podjezična formulacija riluzola
CA2967659A1 (en) * 2014-11-21 2016-05-26 Biohaven Pharmaceutical Holding Company Ltd. Sublingual administration of riluzole
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
ITUB20155193A1 (it) * 2015-11-03 2017-05-03 Italfarmaco Spa Sospensioni orali di Givinostat fisicamente e chimicamente stabili
CN105726477B (zh) * 2016-03-01 2018-10-12 山东司邦得制药有限公司 一种小儿多潘立酮混悬液及其制备方法
CN108721325B (zh) * 2017-04-13 2020-03-06 辽宁大熊制药有限公司 蒙脱石混悬液及其制备方法
US20200289476A1 (en) * 2017-11-28 2020-09-17 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
CN111437256A (zh) * 2019-01-17 2020-07-24 北京万全德众医药生物技术有限公司 一种利鲁唑缓释口服混悬液
CN115025056A (zh) * 2022-06-27 2022-09-09 郑州大学第一附属医院 一种含有替加氟、吉莫斯特和奥替拉西钾的口腔崩解制剂

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP249A (en) 1990-04-24 1993-03-17 Biota Scient Management Pty Ltd Anti-viral compounds.
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
EP1552831B1 (en) * 1999-06-04 2009-01-07 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Use of riluzole for treating multiple sclerosis
EA004251B1 (ru) 1999-08-12 2004-02-26 Эли Лилли Энд Компани Эктопаразитицидные водные суспензионные препараты спинозинов
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6432992B1 (en) 2000-06-05 2002-08-13 Aventis Pharm Sa Use of riluzole or its salts for the prevention and treatment of adrenoleukodystrophy
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
EP2526944B1 (en) 2002-11-15 2016-06-01 Teva Pharmaceutical Industries Limited Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
DK1477166T3 (da) * 2003-04-28 2006-12-11 Biofrontera Bioscience Gmbh Anvendelse af riluzoler kombineret med egnede hjælpe- og tilsætningsstoffer til behandling af sygdomme, som er kendetegnet ved en hyperproliferation af keratinocytter, navnlig neurodermitis og psoriasis
US20050266032A1 (en) 2003-12-17 2005-12-01 Sovereign Pharmaceuticals, Ltd. Dosage form containing multiple drugs
US9492541B2 (en) 2004-09-14 2016-11-15 Sovereign Pharmaceuticals, Llc Phenylepherine containing dosage form
EP1778286A4 (en) 2004-03-03 2009-04-08 Teva Pharma COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
ITMI20061274A1 (it) * 2006-06-30 2008-01-01 Consiglio Nazionale Ricerche Vettori nanoparticellari lipidici contenenti riluzolo e composizioni farmaceutiche che li contengono
US9132071B2 (en) * 2006-07-28 2015-09-15 Santen Sas Compositions containing quaternary ammonium compounds
UA41879U (ru) * 2009-02-03 2009-06-10 Сергей Викторович Фурс Инфракрасный обогревательный прибор

Also Published As

Publication number Publication date
EP2228054A1 (en) 2010-09-15
HRP20130021T1 (hr) 2013-02-28
EP2405890A2 (en) 2012-01-18
BRPI1006418A2 (pt) 2016-11-29
CN102341091B (zh) 2013-08-07
HK1161985A1 (en) 2012-08-17
JP5607083B2 (ja) 2014-10-15
DK2405890T3 (da) 2013-02-04
WO2010102923A2 (en) 2010-09-16
US8765150B2 (en) 2014-07-01
KR101680175B1 (ko) 2016-11-28
CA2748856C (en) 2017-01-03
CL2011002217A1 (es) 2012-03-09
PT2405890E (pt) 2013-02-20
KR20120003854A (ko) 2012-01-11
SMT201300022B (it) 2013-03-08
PE20120649A1 (es) 2012-06-07
EP2405890B1 (en) 2012-11-28
PL2405890T3 (pl) 2013-04-30
CY1113825T1 (el) 2016-07-27
ES2400349T3 (es) 2013-04-09
WO2010102923A3 (en) 2011-03-03
CA2748856A1 (en) 2010-09-16
RU2011141422A (ru) 2013-04-20
US20120039953A1 (en) 2012-02-16
MX2011008922A (es) 2011-12-06
RU2498802C2 (ru) 2013-11-20
JP2012520254A (ja) 2012-09-06
CN102341091A (zh) 2012-02-01
SI2405890T1 (sl) 2013-02-28

Similar Documents

Publication Publication Date Title
CO6410281A2 (es) Suspensiones acuosas de riluzol
AU2014257815A8 (en) Cleansing compositions with improved dispensing and suspension properties
MX2011012196A (es) Composiciones y metodos para el suministro de farmaco.
MY166868A (en) Bactericidal agent composition
DOP2012000090A (es) Composicion de agente tensoactivo estructurada con ion de metal de tierra alcalina y microfibra de celulosa
UA93917C2 (ru) Частички перкарбоната натрия, покрытые оболочкой, моющие и очистительные средства, которые их содержат
EA201101332A1 (ru) Составы
BR112015012599A2 (pt) fibras de baixa densidade e métodos para sua formação
CO7380752A2 (es) Agente de suspensión de minerales, método de fabricación y uso del mismo
AR084328A1 (es) Dispersiones acuosas de copolimero de etileno acido acrilico para liberacion de fragancia en detergentes de lavanderia
MX2012004686A (es) Microfibras de celulosa con una distribucion del tamaño de las particulas para composiciones estructuradas de agentes tensioactivos.
BR112014004362A2 (pt) composição de revestimento, processo para preparar uma composição de revestimento, forma de dosagem e processo para revestir uma forma de dosagem
BR112012021418A2 (pt) limpador de vasos sanitários e método.
MX352814B (es) Composiciones para el cuidado oral que comprenden carbonato de calcio y talco.
BR112012027527A2 (pt) partículas de agente de branqueamento compreendendo percarbonato de sódio e um ativador de branqueamento
AR083403A1 (es) Composiciones detergentes en particulas que comprenden un agente de fluorescencia
AR058107A1 (es) Azodicarbonamida micronizada, su preparacion y su utilizacion
ES2484015T3 (es) Material aislante realizado en material en lámina reciclado revestido con un agente de liberación
BR112013010646A2 (pt) rejunte de epóxi de base aquosa.
CL2013001023A1 (es) Proceso de produccion de particulas detergentes recubiertas que tienen un nucleo y un recubrimiento cuyos pasos comprenden poner en suspension las particulas del nucleo no recubiertas en un lecho fluidizado, atomizar sobre las particulas de nucleo una lechada acuosa que comprende carbonato de sodio incorporado a la mezcla con carboximetilcelulosa de sodio y secar.
BR112014029636A2 (pt) pó detergente secado por atomização
CL2018000964A1 (es) Detergente líquido concentrado
CN103627546A (zh) 一种护肤液体皂
CL2011003334A1 (es) Proceso para elaborar un nanorefuerzo natural, a partir de silicato natural de origen volcánico del tipo montmorillonita sódica con tamaño bajo 2 µm que comprende fraccionamiento y tratamiento en húmedo, incorporando solamente un defloculante– floculante a temperatura ambiente; el nanorefuerzo y su uso para producir nanocompositos.
WO2009034360A3 (en) Shampoo

Legal Events

Date Code Title Description
FC Application refused